Tigerlily Foundation, a national breast cancer nonprofit dedicated to ending cancer disparities for young women?particularly women of color?announced a collaboration with Bristol Myers Squibb (BMS) focused on expanding access to clinical trials and reducing barriers to participation. This work is part of Tigerlily's ONE in a MILLION campaign (#ONEinaMILLION), which aims to reach one million women with education and empowerment around clinical trials. Clinical research remains essential for developing new treatments and improving standards of care for breast cancer.
This campaign helps individuals learn more about and connect to clinical trial opportunities, including studies in triple-negative breast cancer (TNBC). Through this collaboration, Tigerlily Foundation and Bristol Myers Squibb (BMS) are working to increase awareness, education, and engagement around clinical research, with a shared commitment to improving access for communities that have historically been underrepresented in this space. These efforts provide patients with clear, accessible information about their care options while addressing common participation barriers and fostering trust between patients, healthcare providers, and the research community.
This collaboration supports education and awareness about clinical trials and does not constitute medical advice or an endorsement of any specific treatment or study. Patients should speak with their healthcare provider about clinical trial options that may be appropriate for them.
